Irvine-based Allergan Inc. (NYSE:AGN) fired back at activist investor Bill Ackman in a tersely worded letter prompted by Ackman’s conflict of interest charges against Chairman and Chief Executive David Pyott. Allergan, Inc. (NYSE:AGN) net profit margin is 18.50% and weekly performance is -0.01%. On last trading day company shares ended up $159.70. Analysts mean target price for the company is $179.65. Allergan, Inc. (NYSE:AGN) distance from 50-day simple moving average (SMA50) is 13.49%.
Representatives for Bristol-Myers Squibb Co (NYSE:BMY) were before the planning board tonight to detail fresh plans for the development of the tract, which is home to the 200-plus year old Brearley Oak. The drug manufacturer’s plans call for a reduction in total building construction that was previously approved for the site, though there are no immediate plans to actually build on the land. The new plans call for construction of 555,525 square-feet of office space, laid out as four interconnected buildings with a center atrium, Bristol-Myers spokesman Fred Egenolf said. Bristol-Myers Squibb Co (NYSE:BMY) shares advanced 1.15% in last trading session and ended the day on $49.34. BMY gross Margin is 72.40% and its return on assets is 8.00%.Bristol-Myers Squibb Co (NYSE:BMY) quarterly performance is -9.05%.
Boston Scientific Corporation (NYSE:BSX) said recently that it is buying the vascular interventional device division of Bayer AG for $415 million in cash. The deal is expected to clear in the second half of the year, pending regulatory and antitrust considerations. Boston Scientific Corporation (NYSE:BSX) shares moved up 0.23% in last trading session and was closed at $12.83, while trading in range of $12.65 – $12.85. Boston Scientific Corporation (NYSE:BSX) year to date (YTD) performance is 6.74%.
Seattle Genetics (NASDAQ:SGEN) Director Felix Baker purchased 189,611 shares of Seattle Genetics stock on the open market in a transaction dated Friday, May 16th. The shares were purchased at an average cost of $34.07 per share, for a total transaction of $6,460,046.77. Following the completion of the acquisition, the director now directly owns 76,997 shares of the company’s stock, valued at approximately $2,623,288. Seattle Genetics, Inc. (NASDAQ:SGEN) ended the last trading day at $34.36. Company weekly volatility is calculated as 5.01% and price to cash ratio as 11.30.Seattle Genetics, Inc. (NASDAQ:SGEN) showed a negative weekly performance of -7.08%.
Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) reiterated its forecast for full-year revenue growth in the low- to mid-single-digits. It said earnings per share, a key measure of profitability, will likely grow ahead of sales. Sales of hepatitis drug Pegasys–the company’s seventh best-selling product last year–fell, particularly in the U.S. and Europe. Xeloda, which lost patent protection and is exposed to cheaper generics competition in the U.S. and Europe, dropped 19%. In 2013, the treatment ranked fifth among Roche’s top pharmaceutical products. On last trading day company shares ended up $37.74.